Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The British Journal of Dermatology|May 10, 2018
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trialsA Blauvelt, K Reich, K A Papp, et al.The British Journal of Dermatology|September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)C Paul, J Cather, M Gooderham, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 20, 2021
Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONGA Jalili, P Calzavara-Pinton, L Kircik, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 31, 2016
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A Menter, K A Papp, M Gooderham, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 3, 2021
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyondJ Beecker, K A Papp, J Dutz, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2017
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized studyR Bissonnette, R Haydey, L A Rosoph, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.The British Journal of Dermatology|September 4, 2020
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trialA Blauvelt, C Leonardi, B Elewski, et al.Pageof 3